{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:13:00Z","timestamp":1754557980795,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703037"],"award-info":[{"award-number":["81703037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Apatinib is an oral anti\u2010angiogenic drug, its efficacy and prognosis in cervical carcinoma are unclear. This study evaluates the effectiveness and prognostic factors of apatinib in the treatment of recurrent or advanced cervical carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with recurrent or advanced cervical cancer, who agreed to take apatinib, were recruited into this single\u2010center and retrospective study, and administrated apatinib with or without combination of chemo\u2010 or radio\u2010therapy until progressive disease (PD) or unacceptable toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From March 2017 to February 2019, 53 patients were reviewed. Among them, 2 (3.77%) patients occurred complete response, 16 (30.19%) patients showed partial response, 27 (50.95%) patients had stable disease, and 8 (15.09%) patients had PD. The objective response rate and disease control rate (DCR) of these patients were 33.96% and 84.91%, respectively. The DCR of patients younger than 50, nonsquamous carcinoma, first\u2010line apatinib therapy, combined radiotherapy, lesions within radiation field, surgical history, and Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 were significantly higher than other patients (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.05). The median progression\u2010free survival (PFS) and overall survival (OS) were 6.0\u00a0months (95% CI: 4.43\u20137.57) and 8.0\u00a0months (95% CI: 6.52\u20139.48), respectively. The univariable and multivariable analysis showed that the patients with an ECOG performance status score of 2 and further line therapy were associated with poor prognosis in both PFS and OS (PFS: HR\u00a0=8.35, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.000; HR\u00a0=6.66, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.001; OS: HR\u00a0=\u00a07.40, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.000; HR\u00a0=\u00a03.24, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.039), respectively. The most common adverse effects (AEs) were hand\u2010foot syndrome (35.58%), hypertension (18.87%) and fatigue (15.09%). No grade 3 AEs and drug\u2010related death occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The efficacy and prognosis of patients who are in good general condition and first\u2010line apatinib combination therapy may be better than other patients. But further phase III clinical trials should be taken to prove this hypothesis.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.3966","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T09:09:27Z","timestamp":1620983367000},"page":"4282-4290","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1285","authenticated-orcid":false,"given":"Hui","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Cancer Clinical Study Center Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Cancer Clinical Study Center Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijie","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Cancer Clinical Study Center Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-9864","authenticated-orcid":false,"given":"Conghua","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Cancer Clinical Study Center Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Cancer Clinical Study Center Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Key Laboratory of Tumor Biological Behaviors Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"},{"name":"Hubei Cancer Clinical Study Center Zhongnan Hospital of Wuhan University Wuhan People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)02250-2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.01.048"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11373-006-9114-6"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-4-29"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2704"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309748"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01939.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00828-x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.26376"},{"issue":"6","key":"e_1_2_9_12_1","first-page":"4768","article-title":"Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: an observational study","volume":"17","author":"Zhu A","year":"2019","journal-title":"Oncol Lett"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S191736"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008725"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30444-3"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2018.1471315"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3852373"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S230406"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e2"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00858-5"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S214743"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S212536"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019372"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8909"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1148\/94.2.445"},{"issue":"5","key":"e_1_2_9_26_1","first-page":"1012","article-title":"Irradiation\u2010induced angiogenesis through the up\u2010regulation of the nitric oxide pathway: implications for tumor radiotherapy","volume":"63","author":"Sonveaux P","year":"2003","journal-title":"Cancer Res"},{"issue":"14","key":"e_1_2_9_27_1","first-page":"3374","article-title":"Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"59","author":"Gorski DH","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.10.022"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.10.060"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3966","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3966","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:59:46Z","timestamp":1693357186000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1002\/cam4.3966"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3966","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"2020-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}